Catalyst Capital Advisors LLC Has $243,000 Stock Holdings in Boston Scientific Corporation $BSX

Catalyst Capital Advisors LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 43.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,267 shares of the medical equipment provider’s stock after purchasing an additional 687 shares during the quarter. Catalyst Capital Advisors LLC’s holdings in Boston Scientific were worth $243,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. 1248 Management LLC acquired a new stake in Boston Scientific in the first quarter worth $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the first quarter worth $27,000. Sound Income Strategies LLC grew its holdings in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the period. Princeton Global Asset Management LLC acquired a new stake in Boston Scientific in the second quarter worth $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific in the second quarter worth $37,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Barclays raised their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Friday. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific presently has an average rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Stock Down 1.3%

BSX opened at $101.08 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company’s 50-day moving average is $101.14 and its 200 day moving average is $102.00. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The firm has a market capitalization of $149.78 billion, a P/E ratio of 54.06, a PEG ratio of 2.37 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period last year, the firm earned $0.63 earnings per share. The firm’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 170,214 shares of company stock valued at $17,548,337 over the last ninety days. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.